AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
16.88
+1.03 (6.50%)
Jan 21, 2025, 4:00 PM EST - Market closed
AnaptysBio Revenue
AnaptysBio had revenue of $30.02M in the quarter ending September 30, 2024, with 804.67% growth. This brings the company's revenue in the last twelve months to $57.17M, up 282.17% year-over-year. In the year 2023, AnaptysBio had annual revenue of $17.16M with 66.78% growth.
Revenue (ttm)
$57.17M
Revenue Growth
+282.17%
P/S Ratio
8.09
Revenue / Employee
$488,650
Employees
117
Market Cap
513.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
ANAB News
- 14 days ago - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Benzinga
- 5 weeks ago - AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters
- 5 weeks ago - AnaptysBio abandons eczema drug development after mid-stage trial failure - Reuters
- 5 weeks ago - Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Anaptys Announces Participation in November and December Investor Conferences - GlobeNewsWire
- 2 months ago - Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire